|

OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events

RECRUITINGPhase 3Sponsored by Amgen
Actively Recruiting
PhasePhase 3
SponsorAmgen
Started2025-08-22
Est. completion2031-10-20
Eligibility
Age50 Years – 105 Years
Healthy vol.Accepted
Locations186 sites
View on ClinicalTrials.gov →

NCT07136012

Summary

The primary objective is to evaluate the effect of olpasiran, compared to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants at risk for a first major cardiovascular event with elevated lipoprotein(a) (Lp\[a\]).

Eligibility

Age: 50 Years – 105 YearsHealthy volunteers accepted
Inclusion Criteria:

* Age ≥50 years
* Lp(a)≥ 200 nmol/L during screening
* Multiple atherosclerotic cardiovascular disease risk factors, and/or evidence of atherosclerosis

Exclusion Criteria:

* Prior acute atherothrombotic event (myocardial infarction, stroke, transient ischemic attack, acute limb ischemia)
* Prior or planned arterial revascularization
* History of major bleeding disorder

Conditions2

Cardiovascular DiseaseHeart Disease

Locations186 sites

Advanced Cardiovascular LLC
Alexander City, Alabama, 35010
University of Alabama Birmingham Saint Vincents Birmingham
Birmingham, Alabama, 35205
Birmingham Clinical Research
Birmingham, Alabama, 35209
Alliance For Multispecialty Research - Daphne
Daphne, Alabama, 36526
Eastern Shore Research Institute
Fairhope, Alabama, 36532

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.